Pfizer vs Moderna: Which Stock is the Better Buy?

The heated vaccine race wound to a close at the end of 2020. In the end, several companies would release their vaccine to the public. What vaccine you received depended on your area of origin, and largely on timing. However, two companies have appeared to take the lead as the most trusted options at this stage. The two mRNA vaccines are now the most widely used in the Western world. Which company boasts the better stock for investors right now? Let’s jump in.

Pfizer (NYSE:PFE) stock has climbed 18% in 2021 as of mid-afternoon trading on September 27. However, the stock has slipped 5.7% month over month. In Q2 2021, Pfizer delivered revenues of $19 billion. This reflected operational growth of 86%. The company expects to deliver at least 6% CAGR through 2025. Pfizer has established itself as the premier vaccine manufacturer during the crisis. It is also in pole position to provide boosters going forward.

Shares of Moderna (NASDAQ:MRNA) have increased 265% in the year-to-date period. The stock is up nearly 480% year over year. In Q2 2021, the company delivered total revenues of $4.4 billion – up from $67 million in the second quarter of 2020. Modern posted revenue of $6.3 billion for the first six months of 2021 which was up from $75 million in the year-to-date period last year.

Pfizer stock last had a favourable price-to-earnings ratio of 18. It also offers a 3.5% dividend yield. Moderna, meanwhile, looks overheated after a banner year. I’m looking to snatch up the undervalued Pfizer today.